Li Sun

Dr. Li Sun

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2014 in Glia
Verified
Journal Article
Closed access
PDF file
XWXi Wang
Xi Wang
KCKai Cao
Kai Cao
XSXin Sun
Xin Sun
YCYongxiong Chen
Yongxiong Chen
ZDZhaoxia Duan
Zhaoxia Duan
YRyi ren
yi ren

21 January 2019 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
TZTian Zhou
Tian Zhou
YZYiming Zheng
Yiming Zheng
LSLi Sun
Li Sun
SBSmaranda Ruxandra Badea
Smaranda Ruxandra Badea
YJYuanhu Jin
Yuanhu Jin
YRyi ren
yi ren

18 June 2022 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
XYXuegang Yuan
Xuegang Yuan
LSLi Sun
Li Sun
RJRichard Jeske
Richard Jeske
DNDingani Nkosi
Dingani Nkosi
SYSara B. York
Sara B. York
YLYan Li
Yan Li
Human mesenchymal stem cell (hMSC) derived extracellular vesicles (EVs) have shown therapeutic potential in recent studies. However, the corresponding therapeutic components are largely unknown, and scale‐up production of hMSC EVs is a major challenge for translational applications. In the current study, hMSCs were grown as 3D aggregates under wave motion to promote EV secretion. Results demonstrate that 3D hMSC aggregates promote activation of the endosomal sorting complexes required for transport (ESCRT)‐dependent and ‐independent pathways. mRNA sequencing revealed global transcriptome alterations for 3D hMSC aggregates. Compared to 2D‐hMSC‐EVs, the quantity of 3D‐hMSC‐EVs was enhanced significantly (by 2‐fold), with smaller sizes, higher miR‐21 and miR‐22 expression, and an altered protein cargo (e.g., upregulation of cytokines and anti‐inflammatory factors) uncovered by proteomics analysis, possibly due to altered EV biogenesis. Functionally, 3D‐hMSC‐EVs rejuvenated senescent stem cells and exhibited enhanced immunomodulatory potentials. In summary, this study provides a promising strategy for scalable production of high‐quality EVs from hMSCs with enhanced therapeutic potential.

1 July 2023 in Bioactive Materials
Verified
Journal Article
Open access
RJRichard Jeske
Richard Jeske
CLChang Liu
Chang Liu
LDLeanne Duke
Leanne Duke
MCMaria L. Canonicco Castro
Maria L. Canonicco Castro
LMLaureana Jacqueline Muok
Laureana Jacqueline Muok
YLYan Li
Yan Li
Human mesenchymal stromal cells (hMSCs) are mechanically sensitive undergoing phenotypic alterations when subjected to shear stress, cell aggregation, and substrate changes encountered in 3D dynamic bioreactor cultures. However, little is known about how bioreactor microenvironment affects the secretion and cargo profiles of hMSC-derived extracellular vesicles (EVs) including the subset, “exosomes”, which contain therapeutic proteins, nucleic acids, and lipids from the parent cells. In this study, bone marrow–derived hMSCs were expanded on 3D Synthemax II microcarriers in the PBS mini 0.1L Vertical-Wheel bioreactor system under variable shear stress levels at 25, 40, and 64 RPM (0.1–0.3 dyn/cm2). The bioreactor system promotes EV secretion from hMSCs by 2.5-fold and upregulates the expression of EV biogenesis markers and glycolysis genes compared to the static 2D culture. The microRNA cargo was also altered in the EVs from bioreactor culture including the upregulation of miR-10, 19a, 19b, 21, 132, and 377. EV protein cargo was characterized by proteomics analysis, showing upregulation of metabolic, autophagy and ROS-related proteins comparing with 2D cultured EVs. In addition, the scalability of the Vertical-Wheel bioreactor system was demonstrated in a 0.5L bioreactor, showing similar or better hMSC-EV secretion and cargo content compared to the 0.1L bioreactor. This study advances our understanding of bio-manufacturing of stem cell-derived EVs for applications in cell-free therapy towards treating neurological disorders such as ischemic stroke, Alzheimer's disease, and multiple sclerosis.

1 September 2018 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
SHStephanie N. Hurwitz
Stephanie N. Hurwitz
LSLi Sun
Li Sun
KCKalonji Y. Cole
Kalonji Y. Cole
CFCharles R. Ford
Charles R. Ford
JOJames M. Olcese
James M. Olcese
DMDavid Meckes
David Meckes

1 March 2017 in Cell Transplantation
Verified
Journal Article
Open access
ZCZhijian Cheng
Zhijian Cheng
DBDale B. Bosco
Dale B. Bosco
LSLi Sun
Li Sun
XCXiaoming Chen
Xiaoming Chen
YXYunsheng Xu
Yunsheng Xu
YRyi ren
yi ren
Spinal cord injury (SCI) causes functional impairment as a result of the initial injury followed by secondary injury mechanism. SCI provokes an inflammatory response that causes secondary tissue damage and neurodegeneration. While the use of neural stem cell (NSC) engraftment to mitigate secondary injury has been of interest to many researchers, it still faces several limitations. As such, we investigated if NSC-conditioned medium (NSC-M) possesses therapeutic potential for the treatment of SCI. It has been proposed that many of the beneficial effects attributed to stem cell therapies are due to secreted factors. Utilizing primary cell culture and murine models of SCI, we determined that systemic treatment with NSC-M was able to significantly improve motor function and lesion healing. In addition, NSC-M demonstrated significant anti-inflammatory potential in vitro and in vivo, reducing inflammatory cytokine expression in both activated macrophages and injured spinal cord tissues. NSC-M was also able to reduce the expression of inducible nitric oxide synthase (iNOS) within the spleen of injured animals, indicating an ability to reduce systemic inflammation. Thus, we believe that NSC-M offers a possible alternative to direct stem cell engraftment for the treatment of SCI.